Tau is a microtubule-associated protein whose transcript undergoes regulated splicing in the mammalian nervous system. Exon 10 of the gene is an alternatively spliced cassette that is adult-specific and encodes a microtubule-binding domain. Mutations increasing the inclusion of exon 10 result in the production of tau protein which predominantly contains four microtubule-binding repeats and were shown to cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Here we show that exon 10 usage is regulated by CDC2-like kinases CLK1, 2, 3, and 4 that phosphorylate serine-arginine-rich proteins, which in turn regulate pre-mRNA splicing. Cotransfection experiments suggest that CLKs achieve this effect by releasing specific proteins from nuclear storage sites. Our results show that changing pre-mRNA-processing pathways through phosphorylation could be a new therapeutic concept for tauopathies.
INTRODUCTION
Tau is a microtubule-associated protein expressed in the nervous system, where it plays a role in the polymerization and stabilization of microtubules (Delacourte and Buee, 1997) . The human tau gene consists of 16 exons from which six tau protein isoforms are generated in the adult human brain by alternative splicing (Andreadis et al., 1992; Goedert et al., 1989a) . The interaction of tau with microtubules occurs at the C-terminus of the tau protein, where it contains imperfect repeats that act as microtubule-binding domains (Himmler et al., 1989) . One of these repeats is encoded by exon 10 that is alternatively spliced in humans, giving rise to tau with three (3R, exon 10Ϫ) or four (4R, exon 10ϩ) microtubule-binding domains. Alternative splicing of exon 10 is under developmental control in both rodents and humans, with exon 10 inclusion being adult specific. However, in adult human and primate brains, exon 10 remains regulated, whereas in rodents, it is used constitutively (Goedert et al., 1989b; Grover et al., 1999; Kosik et al., 1989) . Although knock-out experiments have revealed that tau gene loss can be compensated for during brain formation (Harada et al., 1994; Ikegami et al., 2000; Takei et al., 2000) , tau protein is extensively studied because it is involved in the pathology of a number of neurodegenerative diseases (Garcia and Cleveland, 2001; . Recently, mutations in the tau gene have been associated with frontotemporal dementia and parkinsonism linked to chromosome 17 3 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., , 2000a . These mutations were missense, deletion, silent, or in-tronic. Most missense mutations act at the protein level and reduce the ability of tau to interact with microtubules (Hasegawa et al., 1998) . Intronic mutations and the exonic mutations N279K, L284L, N296N, S305N, and S305S affect pre-mRNA processing and lead to an increase of exon 10 usage by changing either the 5Ј splice site composition or exonic elements in exon 10 (Clark et al., 1998; D'Souza et al., 1999; Hasegawa et al., 1999; Hutton et al., 1998; Spillantini et al., , 2000b Stanford et al., 2000; Varani et al., 1999) . As a result, the approximately equal ratio of 4R and 3R isoforms is shifted in favor of 4R tau. This change in isoform ratio ultimately leads to the filamentous tau pathology composed of 4R tau. Overexpression of a human 4R isoform in mice leads to a hind-limb clasping phenotype and abnormal tau and neurofilament axonal swellings in the spinal cord (Duff et al., 2000) . In healthy individuals, the normal balance between 3R and 4R tau is achieved by regulated alternative splicing, an important mechanism for creating different protein isoforms from a single gene, which is used in about 60% of all human genes (Mironov et al., 1999; Stamm et al., 2000; International human genome sequencing consortium, 2001) . It has been estimated that up to 15% of genetic defects caused by point mutations in humans manifest themselves as pre-mRNA splicing defects through changes in splice site sequences (Krawczak et al., 1992; Nakai and Sakamoto, 1994) . Splice site choices are regulated by degenerate sequence elements in the RNA, such as the branch point and the 5Ј and 3Ј splice sites, as well as by enhancer or silencer elements (Elliot, 2000; Green, 1991; Krämer, 1996; Moore, 2000) . The high fidelity of splice site selection is the result of cooperative binding of transacting factors to these sequences (Hertel et al., 1997) . The loose consensus sequences, found in exonic elements that can work as either enhancers or silencers, are probably necessary to allow the proper protein coding (Elliot, 2000) . Their importance is underlined by several diseases caused by mutations in exonic enhancers (Cooper and Mattox, 1997; Daoud et al., 2000; Philips and Cooper, 2000; Stoss et al., 2000) .
Two major classes of proteins have been shown to interact with exonic sequence elements: the hnRNPs (Weighardt et al., 1996) and the SR proteins (Fu, 1995; Tacke and Manley, 1999) . These proteins can interact with spliceosomal components (Wu and Maniatis, 1993) and mark or hide splice sites located nearby. As a result, their relative concentrations can dictate splice site usage, both in vivo and in vitro (Cá ceres et al., 1994; Mayeda and Krainer, 1992; Screaton et al., 1995; Wang and Manley, 1995) . The expression levels of various SR proteins (Ayane et al., 1991; Mayeda and Krainer, 1992; Screaton et al., 1995; Zahler et al., 1993) and hnRNPs (Kamma et al., 1995) are variable among tissues and could therefore account for differences in splice site selection. Several examples of antagonistic splicing factors have been described (Cá ceres et al., 1994; Gallego et al., 1997; Mayeda et al., 1993; Polydorides et al., 2000) , where one factor promotes inclusion of an exon and the other factor promotes its skipping. In the nucleus, factors involved in pre-mRNA processing are concentrated in speckles-dynamic structures (Misteli et al., 1997) that are sensitive to phosphorylation (Nayler et al., 1998b) . A number of kinases, phosphorylating RS domains, have been described, among them a U1 70K-associated kinase (Woppmann et al., 1993) , SRPK1 (Gui et al., 1993) , and SRPK2 (Wang et al., 1998) . In addition, four kinases termed CLK (cdc2-like kinases) have been shown to phosphorylate SR proteins and to regulate their subnuclear localization (Colwill et al., 1996a,b; Nayler et al., 1997 Nayler et al., , 1998b . Phosphorylation of SR proteins leads to their release from speckles and probably increases their concentration in the nucleoplasm. As alternative splice site selection is regulated by the relative concentrations of transacting factors, CLK kinases can indirectly govern splice site selection.
Here we show that CLK kinases cause exon 10 skipping of tau, even when regulatory elements of this exon are changed by mutation. These data suggest that a change in phosphorylation of splicing factors could be of therapeutic usage in FTDP-17 and that a misregulation of these factors could be a cause for tauopathies.
RESULTS

mCLK1-4 Promote Skipping of Tau Exon 10
In order to analyze transacting factor regulation of exon 10 splicing, we constructed the minigene SV9/ 10L/11 consisting of exon 10 and its flanking exon and intron regions (Fig. 1A) (Gao et al., 2000) . The mutations N279K, L284L, S305N, M16, and C16 involved in FTDP-17 were introduced into this wild-type background (Fig. 1B) .
Previously, we showed that the SR proteins SF2/ASF, SRp55, and SRp75, splicing regulatory proteins containing an arginine-serine-rich domain (Manley and Tacke, 1996) , promote skipping of exon 10 (Gao et al., 2000) . This shows that alternative splicing patterns of exon 10 can be modified in vivo. We reasoned that a phospho-rylation-mediated release of SR proteins could have a similar effect and therefore tested the murine kinases CLK1, 2, 3, and 4 in similar transfection experiments in HEK293 cells. Without addition of CLKs, exon 10 was skipped in about 30% of the minigene-derived RNA ( Fig. 2A ). This percentage increases in the presence of CLK1 and CLK4 to about 45% (P ϭ 0.056 and P ϭ 0.062, respectively) and is highest with CLK2 (P Ͻ 0.0001) followed by CLK3 (P Ͻ 0.01), where between 60 and 70% of exon 10 is skipped (Fig. 2C ). As this effect could have been the result of different expression levels, we analyzed protein lysates from the same transfection experiments and found similar protein amounts for all four kinases (Fig. 2B ), indicating comparable expression of CLK1-4. Without addition of CLKs, exon 10 was skipped in about 30% of the minigene-derived RNA. This percentage increases in the presence of CLK1 and CLK4 to about 45% and is highest with CLK2 and CLK3, where it is between 60 and 70% (Fig. 2C ). It should be noted that overexpression of CLKs does not change the splicing patterns of other minigenes (data not shown), e.g., GABA A ␥2 alternative 24-nt exon (Ashiya and Grabowski, 1997) , clathrin light-chain B exon EN (Stamm et al., 1992 , insulin receptor exon 11 (Kosaki and Webster, 1993) , and SWAP exon 2A (Sarkissian et al., 1996) . Only with the SRp20 exon 4 was a similar effect on exon skipping found (Stoss et al., 1999) . We conclude that CLKs can stimulate skipping of tau exon 10 in vivo, with CLK2 having the strongest effect. 
mCLK1-4 Promote Exon 10 Skipping in a Heterologous Context
We previously demonstrated that both flanking exons 9 and 11 are involved in fine-tuning regulation of exon 10 (Gao et al., 2000) . We therefore asked whether CLKs could still promote exon 10 skipping in a heterologous background. To test this, we employed a construct where exon 10 is flanked by tat exons . As shown in Fig. 3A , CLK2 promotes exon 10 skipping in this context as well (F ϭ 19.84, df ϭ 2, P ϭ 0.002). However, CLK2 increases exon 10 skipping from 25 to 45% (P ϭ 0.03) (Fig. 3B ), which is a small effect when compared to the tau construct containing the natural flanking exons (Fig. 2C ). In addition, higher amounts of CLK2 (g) must be transfected to achieve this effect (Figs. 3A and 3B) . Similar results were observed with the other CLKs (1, 3, and 4) and constructs flanked by constitutive insulin exons (Gao et al., 2000) (data not shown). We conclude that CLKs induce skipping of exon 10 regardless of genomic context. However, the natural flanking sequences promote the ability of CLKs to cause exon 10 skipping, which is in agreement with our earlier findings (Gao et al., 2000) .
mCLK2 Can Revert the Alternative Splicing Pattern of Most FTDP-17 Mutations Which Enhance Exon 10 Usage
Next, we wished to determine whether CLK2 can revert the missplicing observed in mutations of tau exon 10 associated with FTDP-17. Since the effect of CLK2 is stronger when exon 10 is flanked by the natural tau exons 9 and 11, several of the FTDP-17 mutations were created in the SV9/10L/11 minigene background (Gao et al., 2000) . All of these mutations changed exonic or intronic sequence elements involved in splicing. They were N279K, which creates a purine-rich enhancer; L284L, a silent mutation that destroys a tat-like silencer; S305N, a mutation that improves U1 snRNA binding and possibly destabilizes the hairpin found at the 5Ј splice site of exon 10; and finally the intronic mutation M16 and its compensatory mutation C16, which destroy and respectively restore this hairpin (Fig. 1B) . With the exception of S305N, expressing these constructs in the presence of CLK2 promoted exon 10 skipping that was similar to the effect seen with the wild-type tau minigene SV9/10L/11. In contrast, the catalytically inactive variant CLK2KR (Nayler et al., 1997) had no effect, indicating that skipping of exon 10 is mediated by phosphorylation. As expected, CLK2 had the strongest effect on the L284L mutation, where an exonic silencer sequence was destroyed, and restored exon 10 skipping to levels similar to those of the wt construct (P ϭ 0.848). The only mutation that did not change its splicing pattern in response to CLK2 was S305N (F ϭ 0.02, df ϭ 2, P ϭ 0.980) bearing an improved 5Ј splice site of exon 10 (Figs. 4A and 4B ). Even transfection of 4 g CLK2 did not induce exon 10 skipping (data not shown). The mutation is located at position Ϫ2 of the 5Ј splice site of exon 10, where a guanine is only rarely found and thus improves the 5Ј splice site, so that exon 10 is now constitutively used and no longer subject to regulation. Similar effects of splice site improvement were seen in other neuronal exons (Kuo et al., 1991; Stamm et al., 1999) . We conclude that the phosphorylation induced by CLK2 can compensate for defects in regulatory elements of tau exon 10, as long as the exon can still be alternatively regulated. Furthermore, the change in splicing is most likely the result of the phosphorylation activity and not due to a sequestration of proteins by CLKs, as the CLK2KR mutants have no effect. 
Exon 10 Is Regulated by SRPK1
Another kinase that phosphorylates SR proteins in vitro and regulates spliceosome assembly and intranuclear distribution of splicing factors is SRPK1 (Gui et al., 1994; Papoutsopoulou et al., 1999) . To determine whether SRPK1-mediated phosphorylation of splicing factors has an effect similar to that of CLK2, we tested SRPK1 in cotransfection experiments with the SV9/ 10L/11 minigene. As can be seen in Fig. 5 , SRPK1 stimulates exon 10 skipping (F ϭ 17.51, df ϭ 2, P ϭ 0.03). However, the effect is not as strong as that observed with CLK2 (P ϭ 0.026) (Fig. 7) .
Regulation of Tau Exon 10 by CDK5
CLK2 is a nuclear kinase. Its subnuclear localization and activity are regulated by phosphorylation of serine 141, which is conserved among all CLK family members (Nayler et al., 1998b) . It is likely that this serine residue is the target of upstream kinases that remain to be determined. Recently, it was suggested that CDK5 (or NCLK), the major cyclin-dependent kinase in the brain, is constitutively active in neurons affected with Alzheimer's disease. It is activated by p35, which was shown to be cleaved to the constitutively active form of p25 in Alzheimer's disease. CDK5 controls other proteins, such as DARPP-32, which was shown to regulate a serine/threonine kinase and a serine/threonine phosphatase (Bibb et al., 1999; Patrick et al., 1999) . In addition, CDK5 is found in hyperphosphorylated neurofilaments in Parkinson's disease (Nakamura et al., 1997) . Since CDK5 has multiple cellular substrates (Bibb et al., 1999; Mandelkow, 1999) and is structurally related to CLK2, we asked whether it can influence exon 10 splicing. We analyzed the effect of CDK5 together with its activators p35 and p25 on the SV9/10L/11 minigene. As shown in Fig. 6 , transfection of CDK5 alone (F ϭ 0.124, df ϭ 2, P ϭ 0.886) or together with p35 (F ϭ 0.937, df ϭ 2, P ϭ 0.442) had no significant effect on exon 10 usage. However, in the presence of the constitutive activator p25, CDK5/p25 promotes exon 10 skipping (F ϭ 5.184, df ϭ 2, P ϭ 0.049). This effect is weaker than the one observed with CLK2, although about 10 times more DNA was transfected. We conclude that CDK5 can barely alter the alternative splicing patterns of tau exon 10 in vivo even if it is activated by p25.
FIG. 4. Influence of mCLK2 on exon 10 mutants. (A)
One microgram of the SV9/10L/11 minigene (wt) with the appropriate mutants was cotransfected with 0.5 g of the mCLK2 expression construct into HEK293 cells. The sequences of the mutations are shown in Fig. 1 . As a control, 0.25 g of mCLK2KR was used. CLK2KR is catalytically inactive due to a lysine to arginine exchange at its ATP-binding site (Nayler et al., 1997) . 
DISCUSSION
Missplicing of tau exon 10 is associated with about half of the known cases of FDTP-17 (Spillantini et al., 2000b) and with the pathology of various other neurodegenerative diseases . Several mutations associated with FTDP-17 that promote exon 10 inclusion have been described. Since exon 10 encodes an additional microtubule-binding site, the enhanced expression of these isoforms could result in tau molecules that are more prone to aggregation and formation of filamentous lesions . Here we show that the splicing of tau can be influenced toward exon 10 exclusion in cell culture systems by overexpressing the serine/threonine kinases CLK1-4. Importantly, the RNA-processing pathways of mutations in exonic elements can be altered toward exon 10 skipping. In contrast, the S305N mutation that improves the 5Ј splice site of exon 10 and possibly destabilizes the stem-loop structure behaves like a constitutive exon and can no longer be regulated.
The exact molecular mechanism of CLK action remains to be determined. The action of CLKs on splice site selection is selective, since only tau exon 10 and SRp20 exon 4 (Stoss et al., 1999) , but not four other minigenes tested, were affected. Since CLKs do not bind RNA, the effect is most likely indirect. For example, splicing factors could be released from the speckles, where they are stored. It has been demonstrated that CLKs regulate the intranuclear localization of SR proteins (Duncan et al., 1998; Nayler et al., 1998b) and that phosphorylation of the RS domain is necessary for targeting SR proteins to sites of transcription (Misteli, 2000; Misteli et al., 1998) . To test this hypothesis, we compared the effect of several proteins that are phosphorylated by CLKs in vitro with the CLK effect on exon 10 regulation. All these factors induced exon 10 skipping, although more DNA needed to be transfected to achieve a change in regulation similar to that of the CLKs. Furthermore, quantification demonstrated that mCLK2 was the kinase with the strongest effect on exon 10 regulation (Fig. 7) . This indicates that kinases with similar biochemical properties have different specificities in vivo, by mechanisms that remain to be explored. Since none of the SR proteins tested has a similar strong effect (Fig. 7) , we suspect that several different SR proteins regulate tau exon 10 in vivo. One explanation could be that CLK2 releases a specific subset of splicing regulatory proteins from speckles in a composition or phosphorylation state (Prasad et al., 1999) that is optimal for exclusion of tau exon 10. Another possibility is that CLKs change the ratios of splicing factor isoforms, which have different effects on splice site selection. For example, SRp20 produces isoforms that either include or exclude an RS domain and CLK2 promotes formation of the RS domain-containing form (Stoss et al., 1999) . Since most splicing factors are subject to regulation by alternative splicing (Nayler et al., 1998a) , CLKs might regulate other RS domain-containing proteins as well. Finally, CLKs themselves are regulated by alternative splicing, but their regulatory transacting factors remain to be determined (Duncan et al., 1998) . Thus, our data show how a complicated network of regulatory proteins can be altered by phosphorylation, resulting in specific changes in pre-mRNA-processing pathways.
We found the effect of CLKs more pronounced when tau exon 10 was in its natural rather than in a heterologous context. This is in agreement with our earlier findings (Gao et al., 2000) and strongly suggests that splicing of exon 10 is regulated by more elements than have been assumed so far (D'Souza et al., 1999) . A dependence of alternative exon regulation on flanking exons was also observed in other systems, such as tropomyosin exons 6 and 7 (Guo and Helfman, 1993) , tau exon 6 (Wei and Andreadis, 1998) , fibronectin (Muro et al., 1999) , and myosin light chain (Gallego and Nadal, 1990) . Our results caution that the exclusive analysis of exon 10 variants in exon trap vectors might give erroneous results.
Selective deposition of only some tau isoforms is observed in a number of sporadic neurodegenerative diseases, such as progressive supranuclear palsy, corticobasal degeneration, and Pick's disease . These diseases are frequently associated with missplicing of exon 10 (Chambers et al., 1999) . It is possible that the change in isoform expression is caused by differences in the concentration of transacting factors that regulate pre-mRNA processing. These variations are the likely cause for the tissuespecific action of mutated alleles (Nissim-Rafinia et al., 2000) and probably account for pleiotrophic phenotypes of some mutations in a population (Rave-Harel et al., 1997) . We therefore speculate that changes in the concentration of proteins involved in pre-mRNA processing may contribute to tauopathies by affecting alternative splicing.
Most of these regulatory proteins are released from their intranuclear storage sites by phosphorylation, which would coincide with the different phosphorylation status seen in most of these diseases (Mandelkow and Mandelkow, 1998) . With a better understanding of the molecular mechanisms regulating alternative splicing it is becoming clearer that defects in pre-mRNA splicing have been underestimated as a factor in human disease Philips and Cooper, 2000; Stoss et al., 2000) . A number of studies show that missplicing events causing disease can be changed in cell culture systems (Friedman et al., 1999; Hofmann et al., 2000; Karras et al., 2000; Schmajuk et al., 1999; Wilton et al., 1999) , suggesting that changing splice site selection, e.g., through low-molecular-weight substances affecting phosphorylation, could be a new therapeutic principle.
EXPERIMENTAL METHODS
Cloning and Mutagenesis
Standard cloning techniques were used. Human tau genomic fragments were cloned into pSVIRB. SV9/ 10L/11 (tau minigene) contains the 3Ј 161 nucleotides of tau exon 9 and 1.5 kb of its downstream intron fused to insulin exon 2, tau exon 10, and the proximal portions of its flanking introns (471 bp upstream and 408 bp downstream) and the 5Ј 68 nucleotides of tau exon 11 and 324 nucleotides of its upstream intron fused to insulin exon 3 (Gao et al., 2000) . Mutations (C16 double mutant, combining M5 and M16, N279K, M16 intronic, (Gao et al., 2000; Manley and Tacke, 1996) ; scaffold attachment factor B (Nayler et al., 1998c) ; and mCLK2, SRPK1, and CDK5 (Figs. 2, 5, 6 ). The bars represent 0, 0.5, and 1 g of transfected splicing factors. L284L, S305N) were introduced using the QuickChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions, except that the DpnI digestion was overnight.
The pSPL3 wt construct contains tau exon 10 including 10 nucleotides at the 3Ј intron boundary and 85 nucleotides at the 5Ј boundary flanked by tat exons . CLK1-4 constructs (Nayler et al., 1997 (Nayler et al., , 1998b were described earlier. Eukaryotic expression of other splicing regulator cDNAs (SRp55, SRp75, ASF/SF2, SAF-B, SRPK1) was under control of the CMV promoter.
In Vivo Splicing Assays
In vivo splicing was performed essentially as described (Stoss et al., 1999) . Briefly, 1 g of the reporter gene was transfected together with increasing amounts (0, 0.5, 1 g) of transacting factor constructs in HEK293 cells using the calcium phosphate method. Empty vector (pEGFP-C2, Clontech) was added to ensure that equal amounts of DNA were transfected. Transfection was performed at 37°C in 3% CO 2 overnight. RNA was isolated 17-24 h after transfection using an RNeasy mini kit (Qiagen), following the manufacturer's instructions. RNA was eluted in 40 l RNase-free H 2 O. For reverse transcription, 2 l of isolated RNA was mixed with 5 pmol antisense minigene-specific primer in 2 l 5ϫ RT buffer, 1 l 100 mM DTT, 1 l 10 mM dNTP, 3 l H 2 O, 0.25 l RNase inhibitor, and 0.25 l H Ϫ reverse transcriptase. The tubes were incubated for 45 min in a 42°C water bath.
Two microliters of the RT reaction was mixed with 2.5 pmol of sense and antisense primer each, 10ϫ PCR buffer, 200 mM dNTP, 2 mM MgCl 2 , and 0.1 l of Taq polymerase.
For the tau SV9/10L/11 minigene, reverse transcription followed by PCR using the primers sense INS1 (cag cta cag tcg gaa acc atc agc aag cag) and antisense INS3 (cac ctc cag tgc caa ggt ctg aag gtc acc) was performed. PCR conditions were initial denaturation for 2 min at 94°C; 30 cycles: 30 s denaturation at 94°C, annealing at 55°C for 1 min, extension at 72°C for 1 min, after 30 cycles a final extension at 72°C for 20 min, and cooling to 4°C in a Biometra trio block thermocycler (Gao et al., 2000) .
For the PSL3-wt minigene the following primers were used: pSL3 forward, cgagctc gct tgt tca ctc atc ctt ttt; and pSL3 reverse, cga gct cgc agt gtc cgc aag tgt a. PCR conditions were identical to those for SV9/10L/11 amplification.
Quantification of the Results
PCR products were resolved on a 2% agarose gel and stained with ethidium bromide. Bands were quantified directly from the gel with the Herolab EASY system using Image master VDS and analysis software. The percentage exclusion is the percentage of spliced RNA that contains the exon (IOD of the peak of exclusion band/IOD of the peak of inclusion band ϩ IOD of the peak of exclusion band) ϫ 100. Mean values (Ϯ standard deviation) were calculated from three independent experiments each. Statistical analysis was performed by ANOVA followed by the Scheffé F test for comparison between samples. P Ͻ 0.05 was regarded as significant.
Western blot analysis was performed as described .
